NeoRx' OncoTrac
This article was originally published in The Gray Sheet
Executive Summary
Partner Boehringer Ingelheim files new product licensing application and B-I's subsidiary Dr. Karl Thomae GmbH files a new establishment licensing application for the NR-LU 10 monoclonal antibody diagnostic imaging agent kit for small cell lung cancer, NeoRx announces March 30. The Seattle-based company discovered in January 1992 that it had to conduct new clinicals and file a new PLA/ELA due to a change in the manufacturer for its MAb. Under a 1992 agreement, B-I has marketing rights for OncoTrac and Thomae will manufacture the product
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.